Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr 28;22(2):150-151.
doi: 10.1055/s-0043-1764308. eCollection 2023 Jun.

Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT

Piyush Chandra  1 , Kishore Kumar  2
Affiliations

Screening for Clonal Hematopoiesis for Mitigating the Risk of Hematopoietic Neoplasms after PRRT

Piyush Chandra et al. World J Nucl Med. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest None declared.

Similar articles

See all similar articles

Cited by

References

    1. NETTER-1 Trial Investigators . Strosberg J, El-Haddad G, Wolin E. Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors . N Engl J Med. 2017;376(02):125–135. - PMC - PubMed
    1. Vigne J, Chrétien B, Bignon A L, Bouhier-Leporrier K, Dolladille C. [ 177 Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database . Eur J Nucl Med Mol Imaging. 2022;49(10):3332–3333. - PubMed
    1. Kwekkeboom D J, de Herder W W, Kam B L. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124–2130. - PubMed
    1. Imhof A, Brunner P, Marincek N. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416–2423. - PubMed
    1. Bodei L, Kidd M, Paganelli G. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(01):5–19. - PubMed